Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Operating Leases (2022 - 2026)

Lexeo Therapeutics' Operating Leases history spans 2 years, with the latest figure at $7.8 million for Q4 2023.

  • On a quarterly basis, Operating Leases fell 13.49% to $7.8 million in Q4 2023 year-over-year; TTM through Dec 2023 was $7.8 million, a 13.49% decrease, with the full-year FY2023 number at $7.8 million, down 13.49% from a year prior.
  • Operating Leases hit $7.8 million in Q4 2023 for Lexeo Therapeutics, down from $8.1 million in the prior quarter.
  • Over the last five years, Operating Leases for LXEO hit a ceiling of $9.0 million in Q4 2022 and a floor of $7.8 million in Q4 2023.